UBS Maintains Buy on Cardinal Health, Raises Price Target to $125
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Kevin Caliendo maintains a Buy rating on Cardinal Health (NYSE:CAH) and raises the price target from $122 to $125.

February 05, 2024 | 5:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Kevin Caliendo maintains a Buy rating on Cardinal Health and raises the price target from $122 to $125.
The increase in the price target by UBS analyst Kevin Caliendo for Cardinal Health (CAH) from $122 to $125, while maintaining a Buy rating, suggests a positive outlook on the company's future performance. This adjustment reflects an expectation of upward movement in CAH's stock price in the short term, likely driven by investor optimism following the analyst's updated valuation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100